Combined use of extended-release niacin and atorvastatin: Safety and effects on lipid modification

Chinese Medical Journal

Volumn 122, Issue 14, 2009, Pages 1615-1620

  Sang, Zhen Chi ^a   Wang, Fei ^a   Zhou, Qing ^a   Li, Yue Hua ^a   Li, Yi Gang ^a   Wang, Hong Ping ^a   Chen, Shu Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adverse events; Atorvastatin; Extended release niacin; Lipid modification

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS A; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; NIACIN; PYRROLES;

EID: 70349554061     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.14.003     Document Type: Article

References (22)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N EnglJ Med 1998; 339:1349-1357.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.
4. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003; 6: 179-188.
5. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003; 91: 1304-1310.
6. Lipid Research Clinics Program Group. Lipid and lipoprotein analysis. In: Hainline KJ, Lippel A, eds. Manual of laboratory operations: lipids research clinics program. Bethesda: Public Health Service, NIH; 1982: 1-143.
7. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 1986; 129: 101-123.
8. Warnick GR, Benderson J, Albers JJ. Dextran sulfate- Mg2 precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388.
9. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-156.
10. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards. J Am Coll Cardiol 2001; 38: 2114-2130.
11. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999; 19: 1051-1059.
12. Ganji SH, Tavintharan S, Zhu D. Niacin non-competitively inhibits diacylglycerol acyltransferase-2 (DGAT2) but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45: 1835-1845.
13. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004; 43: 717-724.
14. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolish and reverse cholesterol transport. Circulation 2006; 113: 1140-1150.
15. Assmman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-737.
16. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21: 1783-1789.
17. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992; 93: 102-104.
18. Grundy CM, Vega GL, McGovern ME. Efficacy, safety and tolerability of one-daily niacin for the treatment of dyslipidemia associated with diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002; 162: 1568-1576.
19. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
20. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
21. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93: 307-312.
22. Tavintharan S, Lim SC, Sum CF. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat? Singapore Med J 2005; 46: 519-528.